Randomized, open-label study of the BRIA-IMT regimen and checkpoint inhibitor vs physician’s choice in advanced metastatic breast cancer (BRIA-ABC)
September 10, 2026
A Phase 1 Dose Escalation Study of the Tolerability, Safety, Efficacy and Pharmacokinetics of ZG006 in Small Cell Lung Cancer